Skip to main content

Advertisement

SpringerLink
Log in

New lines in therapy of Raynaud’s phenomenon

  • Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Current knowledge about the pathogenesis of Raynaud’s phenomenon (RP) results in novel approaches for therapy. Vasospasm without endothelial damage is thought to be the main cause for primary RP. The pathogenesis of secondary forms of RP is supposed to be initiated primary by endothelial damage. The aim of the review is to present main groups of medications as well as non-pharmacological regimen, that are used for the treatment of RP. The necessity of immediate assessment and treatment in severe forms of the disease with digital ulcers is highlighted. The mild forms of primary RP can be controlled by non-pharmacologic approaches. If the effect is insufficient, medications of first choice are calcium channel blockers. In the severe forms of the disorder, intravenous infusion of prostacyclin as well as endothelin-1 receptor antagonists and specific inhibitors of phosphodiesterase-5 are the treatment of choice. Treatment in the future may include selective blockers of alpha-2c adrenergic receptors, inhibitors of protein tyrosine kinase and Rho-kinase, as well as calcitonin gene-related peptide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Herrick AL (2003) Treatment of Raynaud’s phenomenon: new insights and developments. Curr Rheumatol Rep 5:168–174

    Article  PubMed  Google Scholar 

  2. Ho M, Belch JJF (1998) Raynaud’s phenomenon: state of the art 1998. Scand J Rheumatol 27:319–322

    Article  PubMed  CAS  Google Scholar 

  3. Ling SM, Wigley FM (1999) Raynaud’s phenomenon in older adults. Diagnostic considerations and management. Drugs Aging 15(3):183–195

    Article  PubMed  CAS  Google Scholar 

  4. Herric AL, Cerrinic MM (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19:4–8

    Google Scholar 

  5. Kahaleh B, Meyer O, Scorza R (2003) Assessment of vascular involvement. Clin Exp Rheumatol 21(S29):S9–S14

    PubMed  CAS  Google Scholar 

  6. Rajagopalan S, Pfenninger D, Kehrer C et al (2003) Increased asymmetric dimethylarginine and endotheline-1 levels in secondary Raynaud’s phenomenon. Arthritis Rheum 48(7):1992–2000

    Article  PubMed  CAS  Google Scholar 

  7. Schachna L, Wigley FM (2002) Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol 14:686–693

    Article  PubMed  CAS  Google Scholar 

  8. Block JA, Sequeira W (2001) Raynaud’s phenomenon. Semin Lancet 357:2042–2048

    Article  CAS  Google Scholar 

  9. Lisse JR. Raynaud’s phenomenon. eMedicine./www.emedicine.com/med/topic1993.htm, last updated 5 April 2006

  10. Wigley FM (2002) Raynaud’s phenomenon. N Engl J Med 347(13):1001–1007

    Article  PubMed  Google Scholar 

  11. Thompson AE, Pope JE (2005) Calcium-channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology 44:145–150

    Article  PubMed  CAS  Google Scholar 

  12. Thompson AE, Shea B, Welch V et al (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44(8):1841–1847

    Article  PubMed  CAS  Google Scholar 

  13. Leighton C (2001) Drug treatment in scleroderma. Drugs 61(3):419–427

    Article  PubMed  CAS  Google Scholar 

  14. Little WC, Cheng CP (1994) Vascular versus myocardial effects of calcium antagonists. Drugs 47(Suppl 4):41–45

    Article  PubMed  CAS  Google Scholar 

  15. Lambova S, Sapundziev L (2007) Comparative study of therapeutic effect of diltiazem, nifedipine and felodipine in patients with primary and secondary Raynaud’s phenomenon. Scripta Scientifica Medica Varna 39(1):31–34

    Google Scholar 

  16. Berkels R, Taubert D, Rosenkranz A, Rösen R (2003) Vascular protective effects of dihydropyridine calcium antagonists. Involvement of endothelial nitric oxide. Pharmacology 69:171–176

    Article  PubMed  CAS  Google Scholar 

  17. Verhaar MC, Honing ML, van Dam T et al (1999) Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res 42:752–760

    Article  PubMed  CAS  Google Scholar 

  18. Maddison P (2002) Prevention of vascular damage in scleroderma with angiotensin-converting enzyme inhibition. Rheumatology 41:965–971

    Article  PubMed  CAS  Google Scholar 

  19. Tiefenbacher CP, Friedrich S, Bleeke T et al (2004) ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. Am J Physiol Heart Circ Physiol 286:H1425–H1432

    Article  PubMed  CAS  Google Scholar 

  20. Dziadzio M, Denton CP, Smith R et al (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma. Arthritis Rheum 42(12):2646–2655

    Article  PubMed  CAS  Google Scholar 

  21. Badesch DB (2000) Continuous intravenous Epoprostenol for pulmonary hypertension due to the scleroderma spectrum disease. Ann Intern Med 132:425–434

    PubMed  CAS  Google Scholar 

  22. McLaughlin VV, Gaine SP, Barst RJ et al (2003) Efficacy and safety of Treprostinil: an Epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41:293–299

    Article  PubMed  CAS  Google Scholar 

  23. Bettoni L, Geri A, Airò P et al (2002) Clinical systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21:244–250

    Article  PubMed  CAS  Google Scholar 

  24. Della Bella S, Molteni M, Mocellin C et al (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat 65:73–83

    Article  PubMed  CAS  Google Scholar 

  25. Mittag MP, Beckheinrich UF (2001) Systemic sclerosis–related Raynaud’s phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 81:294–297

    Article  PubMed  CAS  Google Scholar 

  26. Scorza R, Caronni M, Mascagni B et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized controlled study. Clin Exp Rheumatol 19:503–508

    PubMed  CAS  Google Scholar 

  27. Lambova S, St Kuzmanova, Stoianova L et al (2006) Therapy with iloprost in patients with severe Raynaud’s phenomenon secondary to scleroderma. Rheumatology 1:33–36

    Google Scholar 

  28. Black CM, Halkier-Sorensen L, Belch JJ et al (1998) Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, dosed-comparison study. Br J Rheumatol 37:952–960

    Article  PubMed  CAS  Google Scholar 

  29. Belch JJF, Capell HA, Cooke ED et al (1995) Oral iloprost as a treatment for Raynaud’s syndrome: a double-blind multicentre placebo-controlled study. Ann Rheum Dis 54:197–200

    Article  PubMed  CAS  Google Scholar 

  30. Galie N, Humbert M, Vachiery JL et al (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–1502

    Article  PubMed  CAS  Google Scholar 

  31. Saji T, Ozawa Y, Ishikita T et al (1996) Short term hemodynamic effect of a new oral PgI2 analogue, Beraprost, in pulmonary and secondary pulmonary hypertension. Am J Cardiol 78:244–247

    Article  PubMed  CAS  Google Scholar 

  32. Kamata Y, Kamimura T, Iwamoto M, Minota S (2005) Comparable effects of sildenafil citrate and alprostadil on severe Raynaud’s phenomenon in a patient with systemic sclerosis. Clin Exp Dermatol 30:451

    Article  PubMed  CAS  Google Scholar 

  33. Barst RJ (2007) A review of pulmonary arterial hypertension: role of ambrisentan. Vasc Health Risk Manag 3(1):11–22

    Article  PubMed  CAS  Google Scholar 

  34. Kumana CR, Cheung GTY, Lau CS (2004) Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 63:1522–1524

    Article  PubMed  CAS  Google Scholar 

  35. Rosenkranz S, Diet F, Karasch T et al (2003) Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and Raynaud’s phenomenon. Ann Int Med 139(10):871–873

    PubMed  Google Scholar 

  36. Baumhaekel M, Scheffler P, Boehm M (2005) Use of tadalafil in patient with secondary Raynaud’s phenomenon not responding to sildenafil. Microvasc Res 69:178–179

    Article  PubMed  Google Scholar 

  37. Rajagopalan S, Pfenninger D, Sokmers E et al (2003) Effects of cilostazol in patients with Raynaud’s syndrome. Am J Cardiol 92:1310–1315

    Article  PubMed  CAS  Google Scholar 

  38. Boin F, Wigley M (2005) Understanding, assessing and treating Raynaud’s phenomenon. Curr Opin Rheumatol 17:752–760

    PubMed  CAS  Google Scholar 

  39. Mayes MD (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic diseases. Arthritis Rheum 48(5):1190–1199

    Article  PubMed  CAS  Google Scholar 

  40. Korn JH, Mayes M, Matucci Cerinic M et al (2004) Digital ulcers in systemic sclerosis prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50(12):3985–3993

    Article  PubMed  CAS  Google Scholar 

  41. Ramos-Casals M, Brito-Zerón P, Nardi N et al (2004) Successful treatment of severe Raynaud’s phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology 43(11):1454–1456

    Article  PubMed  CAS  Google Scholar 

  42. Waxman AB (2007) A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Vasc Health Risk Manag 3(1):151–157

    Article  PubMed  CAS  Google Scholar 

  43. Galié N, Badesch D, Oudiz R et al (2005) Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46(3):529–535

    Article  PubMed  Google Scholar 

  44. Vatter H, Seifert V (2006) Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev 24(11):63–76

    Article  PubMed  CAS  Google Scholar 

  45. Anderson ME, Moore TL, Hollis S et al (2002) Digital vascular response to topical glyceril trinitrate as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology 41(3):324–328

    Article  PubMed  CAS  Google Scholar 

  46. Kirou KA, Crow MK (2000) Raynaud’s phenomenon. In: Paget SA et al (eds) Manual of rheumatology and outpatient orthopedic disorders: diagnosis and therapy, 4th edn. Lippincot Williams & Willkins, Philadelphia, pp 82–87

    Google Scholar 

  47. Rembold CM, Ayers CR (2003) Oral l-arginine can reverse digital necrosis in Raynaud’s phenomenon. Mol Cell Biochem 244(1–2):139–141

    Article  PubMed  CAS  Google Scholar 

  48. Tucker AT, Pearson RM, Cooke ED, Benjamin N (1999) Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud’s syndrome: a randomised trial. Lancet 354(9191):1670–1675

    Article  PubMed  CAS  Google Scholar 

  49. Wollersheim H, Thien T, Fennis J et al (1986) Double-blind, placebo-controlled study of prazosin in Raynaud’s phenomenon. Clin Pharmacol Ther 40(2):219–225

    PubMed  CAS  Google Scholar 

  50. Wollersheim H, Thien T (1988) Dose-response study of prazosin in Raynaud’s phenomenon: clinical effectiveness versus side effects. J Clin Pharmacol 28(12):1089–1093

    PubMed  CAS  Google Scholar 

  51. Flavahan NA, Cooke JP, Shepherd JT, Vanhoutte PM (1987) Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential distribution in arteries of the limbs. J Pharmacol Exp Ther 241(2):361–365

    PubMed  CAS  Google Scholar 

  52. Chotani MA, Flavahan S, Mitra S et al (2000) Silent alpha-2c-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 278(4):H1075–H1083

    PubMed  CAS  Google Scholar 

  53. Wise RA, Wigley FM, White B et al (2004) Efficacy and tolerability of selective alpha - 2c-adrenergic, c receptor blocker in recovery from cold-induced vasospasm in scleroderma patients. Arthritis Rheum 50(12):3994–4001

    Article  PubMed  CAS  Google Scholar 

  54. Furspan PB, Chatterjee S, Robert R Freedman RR (2004) Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud’s disease. Arthritis Rheum 50(5):1578–1585

    Article  PubMed  CAS  Google Scholar 

  55. Furspan PB, Chatterjee S, Mayes MD, Freedman RR (2005) Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud’s phenomenon. Rheumatology 44:488–494

    Article  PubMed  CAS  Google Scholar 

  56. Bailey SR, Eid AH, Mitra S et al (2004) Rho-kinase mediates cold-induced constriction of cutaneous arteries: role of alpha 2C-adrenoreceptor translocation. Circ Res 94:1367–1374

    Article  PubMed  CAS  Google Scholar 

  57. Fukumoto Y, Mohri M, Inokuchi K et al (2007) Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol 49:117–121

    Article  PubMed  CAS  Google Scholar 

  58. Inokuchi K, Ito A, Fukumoto Y, Matoba T (2004) Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J Cardiovasc Pharmacol 44:275–277

    Article  PubMed  CAS  Google Scholar 

  59. Tanaka K, Minami H, Kota M et al (2005) Treatment of cerebral vasospasm with intra-arterial fasudil hydrochloride. Neurosurgery 56:214–223

    Article  PubMed  Google Scholar 

  60. Yamamoto Y, Ikegaki I, Sasaki Y, Uchida T (2000) The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit. J Cardiovasc Pharmacol 35(2):203–211

    Article  PubMed  CAS  Google Scholar 

  61. Cracowski JL, Carpentier PH, Imbert B et al (2002) Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud’s phenomenon. Arthritis Rheum 46(5):1319–1323

    Article  PubMed  CAS  Google Scholar 

  62. Denton CP, Bunce TD, Dorado MB et al (1999) Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology 38:309–315

    Article  PubMed  CAS  Google Scholar 

  63. Mavrikakis ME, Lekakis JP, Papamichael CM et al (2003) Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud’s phenomenon secondary to systemic sclerosis. Int J Vitam Nutr Res 73(1):3–7

    Article  PubMed  CAS  Google Scholar 

  64. Muir AH, Robb R, McLaren M et al (2002) The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo controlled trial. Vasc Med 7(4):265–267

    Article  PubMed  Google Scholar 

  65. Gasser P, Martina B, Dubler B (1997) Reaction of capillary blood cell velocity in nailfold capillaries to l-carnitine in patients with vasospastic disease. Drugs Exp Clin Res 23(1):39–43

    PubMed  CAS  Google Scholar 

  66. Bunker CB, Terenghi G, Springall DR et al (1990) Deficiency of calcitonin gene-related peptide in Raynaud’s phenomenon. Lancet 336:1530–1533

    Article  PubMed  CAS  Google Scholar 

  67. Bunker CB, Reavley C, O’Shaughnessy DJ, Dowd PM (1993) Calcitonin-gene related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet 342:80–83

    Article  PubMed  CAS  Google Scholar 

  68. Coleiro B, Marshall SE, Denton CP et al (2001) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 40:1038–1043

    Article  PubMed  CAS  Google Scholar 

  69. Ihler G, Chami-Stemman H (2003) 7-oxo-DHEA and Raynaud’s phenomenon. Med Hypotheses 60(3):391–397

    Article  PubMed  CAS  Google Scholar 

  70. Fraenkel L, Zhang Y, Chaisson CE et al (1998) The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 129:208–211

    PubMed  CAS  Google Scholar 

  71. Momoi H, Ikomi F, Ohhashi T (2003) Estrogen-induced augmentation of endothelium-dependent nitric oxide-mediated vasodilation in isolated rat cerebral small arteries. Jpn J Physiol 53:193–203

    Article  PubMed  CAS  Google Scholar 

  72. Lekakis J, Papamichael C, Mavrikakis M (1998) Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud’s phenomenon secondary to systemic sclerosis. Am J Cardiol 82:1555–1557

    Article  PubMed  CAS  Google Scholar 

  73. Postlethwaite AE, Chiang TM (2007) Platelet contribution to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 19:574–579

    Article  PubMed  Google Scholar 

  74. Ames PR, Lupoli S, Alves J et al (1997) The coagulation/fibrinolytic balance in systemic sclerosis: evidence for a haematological stress syndrome. Br J Rheumatol 36:1045–1050

    Article  PubMed  CAS  Google Scholar 

  75. Denton CP, Howell K, Stratton RJ, Black CM (2000) Long-term low molecular weight heparin therapy for severe Raynaud’s phenomenon: a pilot study. Clin Exp Rheumatol 18(4):499–502

    PubMed  CAS  Google Scholar 

  76. Fritzler MJ, Hart DA (1990) Prolonged improvement of Raynaud’s phenomenon and scleroderma after recombinant tissue plasminogen activator therapy. Arthritis Rheum 33(2):274–276

    Article  PubMed  CAS  Google Scholar 

  77. Cimminiello C (1996) Clinical trials with defibrotide in vascular disorders. Semin Thromb Hemost 22(Suppl 1):29–34

    PubMed  Google Scholar 

  78. Eberhardt RT, Coffman JD (2000) Drug treatment of peripheral vascular disease. Heart Dis 2(1):62–74

    PubMed  CAS  Google Scholar 

  79. Hirschl M, Katzenschlager R, Francesconi C, Kundi M (2004) Low level laser therapy in primary Raynaud’s phenomenon—results of a placebo-controlled, double-blind intervention Study. J Rheumatol 31:2408–2412

    PubMed  Google Scholar 

  80. al-Awami M, Schillinger M, Maca T et al (2004) Low level laser therapy for treatment of primary and secondary Raynaud’s phenomenon. Vasa 33:25–29

    Article  PubMed  CAS  Google Scholar 

  81. Balogh B, Mayer W, Vesely M et al (2002) Adventitial stripping of the radial and ulnar arteries in Raynaud’s disease. J Hand Surg 27A:1073–1080

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic of Rheumatology, Medical University, 15A “Vasil Aprilov” Blvd, 4002, Plovdiv, Bulgaria

    Sevdalina Nikolova Lambova

  2. Department for Internal Medicine and Rheumatology, Justus-Liebig University Giessen, Giessen, Germany

    Ulf Müller-Ladner

  3. Department for Rheumatology and Clinical Immunology, Kerckhoff Clinic, Bad Nauheim, Germany

    Ulf Müller-Ladner

Authors
  1. Sevdalina Nikolova Lambova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulf Müller-Ladner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sevdalina Nikolova Lambova.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lambova, S.N., Müller-Ladner, U. New lines in therapy of Raynaud’s phenomenon. Rheumatol Int 29, 355–363 (2009). https://doi.org/10.1007/s00296-008-0792-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-008-0792-4

Keywords

Search

Navigation